A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development.
The SCULPT™ process builds and evaluates small molecule libraries, consisting of thousands to millions of members. Iterations are performed until …
No services posted yet
This data is part of our proprietary analytics report:
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality